Vasorelaxant effect of Win 55,212-2 in rat aorta: New mechanisms involved

Vascular Pharmacology

Volumn 46, Issue 1, 2007, Pages 16-23

  Dannert, M T ^a   Alsasua, A ^a   Herradon, E ^b   Martin M I ^b   Lopez Miranda V ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

Cannabinoid receptors; Rat aorta; Vanilloid receptors; Vasorelaxation; WIN 55,212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CAPSAICIN; CAPSAZEPINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PERTUSSIS TOXIN; VANILLOID RECEPTOR 1;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DESENSITIZATION; DRUG EFFICACY; DRUG INHIBITION; MALE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PRIORITY JOURNAL; RAT; THORACIC AORTA; VASCULAR ENDOTHELIUM; VASCULAR RING; VASODILATATION;

ANIMALS; AORTA, THORACIC; BIOLOGICAL FACTORS; CALCITONIN GENE-RELATED PEPTIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; MALE; MORPHOLINES; NAPHTHALENES; NITRIC OXIDE; PROSTAGLANDINS; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; TRPV CATION CHANNELS; VASODILATION; VASODILATOR AGENTS;

EID: 33845206906     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2006.06.005     Document Type: Article

References (40)

1. + Current. J. Biol. Chem. 278 46 (2003) 46188-46194
2. Bouaboula M., Desnoyer N., Carayon P., Combes T., and Casellas P. Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation. Mol. Pharmacol. 55 (1999) 473-480
3. Chaytor A.T., Martin P.E., Evans W.H., Randall M.D., and Griffith T.M. The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J. Physiol. 520 (1999) 539-550
4. Deutsch D.G., Goligorsky M.S., Schmid P.G., Krebsbach R.J., Schmid R.J., Das S.K., Dey S.K., Arreaza G., Thorup C., Stefano G., and Moore L.C. Production and physiological actions of anandamide in the vasculature of the rat kidney. J. Clin. Invest. 100 (1997) 1538-1546
5. Duncan M., Kendall D.A., and Ralevic V. Effect of Win 55,212, a cannabinoid receptor agonist, on sensory neurotransmission in the rat isolated mesenteric arterial bed. Br. J. Pharmacol. 135 (2001) (65 pp.)
6. Duncan M., Kendall D.A., and Ralevic V. Characterization of cannabinoid modulation of sensory neurotransmission in the rat isolated mesenteric arterial bed. J. Pharmacol. Exp. Ther. 311 (2004) 411-419
7. Fleming I., Schermer B., Popp R., and Busse R. Inhibition of the production of endothelium-derived hyperpolarizing factor by cannabinoid receptor agonists. Br. J. Pharmacol. 126 (1999) 949-960
8. Gebremedhin D., Lange A.R., Campbell W.B., Hillard C.J., and Harder D.R. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am. J. Physiol. 276 (1999) H2085-H2093
9. Grainer J., and Boachie-Ansah G. Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels. Br. J. Pharmacol. 134 (2001) 1003-1012
10. Harris D., Mcculloch A.I., Kendall D.A., and Randall M.D. Characterization of vasorelaxant responses to anandamide in the rat mesenteric arterial bed. J. Physiol. 539 (2002) 893-902
11. Hillard C.J. Endocannabinoids and vascular function. J. Pharmacol. Exp. Ther. 294 (2000) 27-32
12. Ho W.S., and Hiley R.C. Endothelium-independent relaxation to cannabinoids in rat-isolated mesenteric artery and role of Ca++ influx. Br. J. Pharmacol. 139 (2003) 585-597
13. Holland M., Challis R.A., Standen N.B., and Boyle J.P. Cannabinoid CB1 receptors fail to cause relaxation, but couple via Gi/Go to inhibition of adenylyl cyclase in carotid artery smooth muscle. Br. J. Pharmacol. 128 (1999) 597-604
14. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., and Pertwee R.G. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol. Rev. 54 2 (2002) 161-202
15. Jarai Z., Wagner J.A., Varga K., Lake K.D., Compton D.R., Martin B.M., Zimmer A.M., Bonner T.I., Buckley N.E., Mezey E., Razdan R.K., Zimmer A., and Kunos G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. 96 (1999) 14136-14141
16. 1 receptors in the rat and mouse. Eur. J. Pharmacol. 391 (2000) 151-161
17. Lopez-Miranda V., Herradon E., Dannert M.T., Alsasua A., and Martin M.I. Anandamide vehicles: a comparative study. Eur. J. Pharmacol. 505 1-3 (2004) 151-161
18. Mukhopadhyay S., Chapnick B.M., and Howlett A.C. Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am. J. Physiol, Heart Circ. Physiol. 282 6 (2002) H2046-H2054
19. Offertáler L., Mo F.M., Bátkai S., Liu J., Begg M., Razdan R.K., Martin B.R., Bukoski R.D., and Kunos G. Selective ligands and cellular effectors of a G Protein-coupled endothelial cannabinoid receptor. Mol. Pharmacol. 63 (2003) 699-705
20. O'Sullivan S.E., Kendall D.A., and Randall M.D. Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries. Br. J. Pharmacol. 142 (2004) 435-442
21. O'Sullivan S.E., Kendall D.A., and Randall M.D. Vascular effects of Delta9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta. Eur. J. Pharmacol. 507 1-3 (2005) 211-221
22. Palmer S.L., Thakur G.A., and Makriyannis A. Cannabinergic ligands. Chem. Phys. Lipids 121 1-2 (2002) 3-19
23. Plane F., Holland M., Waldron G.J., Garland G.J., and Boyle J.P. Evidence that anandamide and EDHF act via different mechanisms in rat isolated mesenteric arteries. Br. J. Pharmacol. 121 (1997) 1509-1511
24. Pratt P.F., Hillard C.J., Edgemond W.S., and Campbell W.B. N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am. J. Physiol, Heart Circ. Physiol. 43 (1998) H375-H381
25. Ralevic V. Cannabinoid modulation of peripheral autonomic and sensory transmission. Eur. J. Pharmacol. 472 (2003) 1-21
26. Ralevic V., and Kendall D.A. Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in rat mesenteric arterial bed. Eur. J. Pharmacol. 418 (2001) 117-125
27. Ralevic V., Kendall D.A., Zygmunt P.M., Movahed P., and Högestätt E.D. Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed. Br. J. Pharmacol. 130 (2000) 1483-1488
28. Randall M.D., and Kendall D.A. The involvement of an endogenous cannabinoid in EDHF-mediated vasorelaxation in the rat coronary vasculature. Eur. J. Pharmacol. 335 (1997) 205-209
29. Randall M.D., Alexander S.P.H., Bennet T., Boyd E.A., Fry J.R., Gardiner S.M., Kemp P.A., McCulloch A.I., and Kendall D.A. An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem. Biophys. Res. Commun. 229 (1996) 114-120
30. Randall M.D., Harris D., Kendall D.A., and Ralevic V. Cardiovascular effects of cannabinoids. Pharmacol. Ther. 95 (2002) 191-202
31. Randall M.D., Kendall D.A., and O'Sullivan S. The complexities of the cardiovascular actions of cannabinoids. Br. J. Pharmacol. 142 (2004) 20-26
32. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrié P., Breliére J.C., and Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350 (1994) 240-244
33. Rinaldi-Carmona M., Barth F., Millan J., Derocq J.M., Casellas P., Congy C., Oustric D., Sarran M., Bouaboula M., Calandra B., Portier M., Shire D., Breliére J.C., and Le Fur G. SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284 (1998) 644-650
34. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., and Davis J.B. The endogenous lipid anandamide is a full agonist at the humen vanilloid receptor (hVR1). Br. J. Pharmacol. 129 (2000) 227-230
35. Vanheel B., and Van de Voorde J. Regional differences in anandamide- and methanandamide-induced membrana potencial changes in rat mesenteric arteries. J. Pharmacol. Exp. Ther. 296 (2001) 322-328
36. Wagner J.A., Varga K., Jarai Z., and Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33 (1999) 4529-4534
37. White R., and Hiley C.R. The actions of some cannabinoid receptor ligands in the rat isolated mesenteric artery. Br. J. Pharmacol. 125 (1998) 533-541
38. White R., and Hiley C.R. The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery. Br. J. Pharmacol. 125 (1998) 689-696
39. White R., Ho W.S., Bottrill F.E., Ford W.R., and Hiley C.R. Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. Br. J. Pharmacol. 134 (2001) 921-929
40. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sørgård M., Di Marzo V., Julius D., and Högestätt E.D. Vanilloid receptors on sensory nerves mediated the vasodilator action of anandamide. Nature 400 (1999) 452-457